<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147886</url>
  </required_header>
  <id_info>
    <org_study_id>BB-MJD-201</org_study_id>
    <nct_id>NCT02147886</nct_id>
  </id_info>
  <brief_title>Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioblast Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioblast Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled
           study without a placebo arm.

        -  Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta
           in 2 doses, once weekly for 22 weeks (total of 24 weeks of treatment).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 weeks</time_frame>
    <description>Safety will be evaluated on the basis of the following assessments:
Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>28 weeks</time_frame>
    <description>Safety will be evaluated on the basis of the following assessments:
Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>28weeks</time_frame>
    <description>Safety will be evaluated on the basis of the following assessments:
Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>28weeks</time_frame>
    <description>Safety will be evaluated on the basis of the following assessments:
Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory tests</measure>
    <time_frame>28weeks</time_frame>
    <description>Safety will be evaluated on the basis of the following assessments:
Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease markers</measure>
    <time_frame>27 weeks</time_frame>
    <description>Changes in disease markers will be assessed based on the following assessments:
Scale for the Assessment and Rating of Ataxia (SARA); Neurological Examination Score for Spinocerebellar Ataxia (NESSCA); Change in BMI - screening, spinocerebellar Ataxia Functional Tests; quality of life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biochemical marker</measure>
    <time_frame>27 weeks</time_frame>
    <description>Assessment of disease biochemical marker neuron specific enolase (NSE) and protein S 100 B (S100B)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Machado-Joseph Disease / Spinocerebellar Ataxia 3</condition>
  <arm_group>
    <arm_group_label>Cabaletta 15gr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabaletta 15gr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabaletta 30gr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabaletta 30gr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabaletta for IV infusion once weekly during 24 weeks</intervention_name>
    <description>Cabaletta for IV infusion once weekly</description>
    <arm_group_label>Cabaletta 15gr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabaletta for IV infusion once weekly during 24 weeks</intervention_name>
    <arm_group_label>Cabaletta 30gr</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, 18 - 75 years

          2. Clinically diagnosed as Machado-Joseph disease/Spinocerebellar ataxia 3 confirmed by
             genetic testing

          3. With disease stage 2 or less

          4. Stable doses of all medications for 30 days prior to study entry and for the duration
             of the study.

          5. Body Mass Index (BMI) ≤32 kg/m2.

          6. Ability to ambulate with or without assistance

        Exclusion Criteria:

          1. Diabetes mellitus type 1 or 2

          2. Other major diseases

          3. Uncontrolled heart disease, chronic heart failure (CHF).

          4. Other neurological diseases.

          5. Ataxia derived from any other cause than genetically-confirmed spinocerebellar ataxia

          6. Presence of psychosis, bipolar disorder, untreated depression

          7. History of malignancy (except non-invasive skin malignancy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Gordon, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center Kfar Saba Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioblast, Randomized, parallel-group, and dose-controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

